Retrospective safety testing of the CT Clock method for identifying treatment-eligible patients with ischaemic stroke of unknown onset time: Study Protocol

This study protocol outlines a retrospective safety analysis of the "CT Clock" method, a simple technique using standard CT scans to identify ischaemic stroke patients with unknown onset times who may safely receive thrombolysis beyond the standard four-and-a-half-hour window, aiming to expand treatment access to hospitals lacking advanced imaging capabilities.

The Gist

The Big Picture: A Race Against Time

Imagine a stroke as a sudden traffic jam in the brain's highway. A blood clot blocks the road, starving the brain cells of oxygen. To fix this, doctors have a "clot-busting" drug (thrombolysis) that can clear the road. However, this drug is like a highly volatile explosive: it works wonders if used quickly (within 4.5 hours), but if used too late, it might cause a dangerous explosion (bleeding in the brain).

Currently, about three-quarters of stroke patients arrive at the hospital too late, or nobody knows exactly when the "traffic jam" started. For these patients, the standard rule is: "No drug, because we don't know if it's safe."

Usually, to decide if it's safe to give the drug late, hospitals need a super-advanced, expensive brain scan (like a high-tech satellite view) to see if the brain tissue is still alive. But many hospitals, especially outside big cities, don't have these super-scans. This means patients in those areas miss out on life-saving treatment.

The Solution: The "CT Clock"

The researchers have invented a simple tool called the CT Clock.

Think of a standard CT scan (the basic brain scan everyone gets) as a black-and-white photo. As a stroke gets older, the injured brain tissue starts to look darker, like a bruise fading into a shadow. The "CT Clock" is a method where doctors look at this standard photo, measure how dark the injured area is compared to the healthy area, and use that darkness to guess:

1. How old is the stroke? (Is it still fresh, or has it been there too long?)
2. Is the tissue still alive? (Is there hope, or is it too late?)

If the "darkness" is very slight, or if the scan looks normal despite the patient having severe symptoms, the CT Clock says, "It's safe to use the clot-busting drug."

What This Paper Is Actually Doing

This document is not a report on a finished medical breakthrough. It is a study plan (a recipe for a future experiment).

The researchers are proposing a "safety check" before they try this method on real patients in the future. Here is the plan in simple steps:

1. The "Time Travel" Test (Retrospective Study)
Instead of testing the method on new patients right now, they are going to look back at the past. They will dig through the hospital records of patients who already had a stroke and already received the clot-busting drug at the Royal Infirmary of Edinburgh.

2. The Blind Review
They will take the old brain scans of these patients and show them to doctors who didn't know the outcome. These doctors will use the "CT Clock" rules to guess: "Based on this scan, should this patient have gotten the drug?"

3. The Safety Check
Then, they will compare the doctors' guesses with what actually happened to the patients.

• The Question: Did the patients that the CT Clock said were "safe to treat" actually have bad side effects (like brain bleeding or getting worse)?
• The Goal: They want to prove that using the CT Clock to pick patients is just as safe as the current, more complex methods.

4. The "Practice Run" for the Real Thing
If this safety check goes well, it will give them the green light to do a bigger, real-world test in the future. That future test would involve using the CT Clock in hospitals that don't have the fancy super-scans, to see if it helps more people get treated.

Key Rules of the Game

• No New Patients: This study doesn't involve treating anyone new. It's purely looking at data from the past.
• Privacy First: All patient names are hidden. The researchers are like detectives looking at case files without knowing who the people are.
• The "Favorable" Result: A "good" result from the CT Clock is when the scan shows the stroke is either very new (not very dark) or the scan looks normal despite the symptoms. These are the patients they hope to treat.

Summary

Think of this paper as a safety inspection report for a new bridge. The researchers have built a new way to cross the river (the CT Clock method) that doesn't require expensive tolls (advanced scans). Before they let cars drive over it, they want to inspect the blueprints and look at test drives from the past to make sure the bridge won't collapse.

If this "inspection" proves the bridge is safe, they will then build the real bridge and open it to traffic, potentially saving thousands of people who currently can't cross the river because they don't have a ticket for the expensive toll.

Technical Summary

Based on the provided study protocol, here is a detailed technical summary of the research.

1. Problem Statement

• Clinical Gap: Approximately 74,000 patients with ischemic stroke in the UK annually present to the hospital either late (>4.5 hours after symptom onset) or with an unknown time of onset. These patients are currently ineligible for intravenous thrombolysis (clot-busting drugs), the standard of care for reducing disability and death, because the safety window has passed.
• Infrastructure Limitation: Advanced imaging (CT Perfusion or MRI) can identify salvageable brain tissue in these late-presenting patients, allowing for safe thrombolysis up to 9 hours or in unknown onset scenarios. However, roughly 50% of UK centers (and many globally) lack access to this advanced imaging.
• Safety Concern: Thrombolysis carries a risk of symptomatic intracranial hemorrhage (SICH) and neurological deterioration. There is a critical need to identify a method that is both widely accessible (requiring only standard CT) and safe for selecting patients who will benefit from treatment without increasing the risk of harm.

2. Methodology

This study is a retrospective safety analysis of the "CT Clock" method using existing NHS Lothian data.

• Study Design: Single-center, retrospective cohort study at the Royal Infirmary of Edinburgh (RIE).
• Data Source: Routinely collected electronic health records and imaging data from adult patients treated with thrombolysis over a 3+ year period.
• The CT Clock Method:
  • Principle: As ischemic brain tissue evolves, it undergoes edema, causing a decrease in CT attenuation (darkening). The method measures the ratio of attenuation in the ischemic lesion versus contralateral normal brain.
  • Thresholds:
    • Time Estimation: An attenuation ratio >0.82 predicts stroke onset <4.5 hours (97% sensitivity, 83% specificity).
    • Viability Estimation: An attenuation ratio >0.87 predicts viable brain tissue (86% sensitivity, 91% specificity).
    • Clinical-Imaging Mismatch: Patients with severe symptoms (NIHSS >11) but no visible lesion on CT are also considered "favorable" candidates, as this suggests early-stage ischemia not yet visible on standard CT.
  • Classification:
    • Favorable Result: Visible lesion with ratio >0.82 OR no visible lesion (mismatch).
    • Non-Favorable Result: Visible lesion with ratio ≤0.82.
• Data Collection & Analysis:
  • Sample Size: Targeting ~320–422 patients. The study will enrich the cohort with patients who experienced Early Neurological Deterioration (END) to ensure 30% of the sample has END, providing sufficient power for non-inferiority testing.
  • Assessors:
    • Index Testing: Front-line clinicians (stroke clinicians/radiologists) will perform CT Clock assessments on baseline non-enhanced CTs.
    • Reference Testing: An expert will review all imaging (including CT Angio/Perfusion if available) to establish a reference standard.
  • Primary Endpoint: The proportion of patients experiencing Early Neurological Deterioration (END) within 7 days post-thrombolysis, comparing those with "Favorable" vs. "Non-Favorable" CT Clock results.
  • Statistical Approach: Non-inferiority testing to determine if the rate of END in the "Favorable" group is not significantly higher than in the "Non-Favorable" group.

3. Key Contributions

• Accessibility: The protocol proposes a method that relies solely on standard non-enhanced CT, which is available in almost all hospitals globally, eliminating the barrier of advanced imaging availability.
• Safety Validation: This is the first study designed specifically to validate the safety of using the CT Clock to select patients for thrombolysis in the absence of advanced imaging, addressing the primary concern of hemorrhagic risk.
• Operational Feasibility: Previous feasibility studies cited in the protocol indicate the method is quick (<5 minutes) and easy for front-line clinicians to use, suggesting high potential for real-world implementation.
• Refinement of Criteria: The study aims to refine the definition of a "favorable" result to maximize the inclusion of treatable patients while maintaining safety margins.

4. Results

• Note: As this document is a Study Protocol (a plan for future research), no empirical results or outcomes are reported.
• The document outlines the expected outcomes: The researchers aim to demonstrate that patients selected via the CT Clock method have a rate of neurological deterioration comparable to those selected via standard criteria, thereby proving the method is safe for clinical use.

5. Significance

• Global Impact: If successful, this study will pave the way for a prospective clinical trial. A successful outcome would allow hospitals without advanced imaging capabilities (particularly in rural areas and developing nations) to safely expand thrombolysis treatment to patients who currently receive no effective therapy.
• Public Health: Given that ~74,000 UK patients annually fall into this "untreatable" category, implementing this method could significantly reduce global stroke-related disability and mortality.
• Cost-Effectiveness: The method utilizes existing hardware and software, requiring no new capital investment for hospitals, making it a highly scalable solution for stroke care equity.
• Next Steps: Upon successful safety validation, the researchers plan to move to prospective clinical testing to establish the method as a routine standard of care.